Xeris Biopharma (NASDAQ:XERS) Releases Earnings Results, Misses Estimates By $0.19 EPS

Xeris Biopharma (NASDAQ:XERS) announced its earnings results on Thursday. The company reported ($0.18) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19), FiscalAI reports. The company had revenue of $92.10 million for the quarter, compared to analyst estimates of $90.12 million. Xeris Biopharma had a return on equity of 735.00% and a net margin of 3.81%.

Here are the key takeaways from Xeris Biopharma’s conference call:

• Second-quarter revenue reached a record $92.1 million, with net product revenue up 34% year over year to $91 million; adjusted EBITDA increased more than 50% to $19.3 million.
• RECORLEV revenue surged 81% to $56.8 million, supported by record referrals, new patient starts, and prescriber growth. Management expects the expanded commercial team to contribute further in the second half.
• Xeris raised and narrowed full-year 2026 revenue guidance to $385 million-$390 million, citing sustained portfolio momentum and an expected rebound in Gvoke, while KEVEYIS received a patent allowance that could extend protection through at least 2039.
• The company fully retired its $34 million of convertible debt in July, eliminating approximately $3 million in annual interest expense and simplifying the balance sheet, although the transaction generated a one-time, non-cash GAAP charge of about $31 million in the second quarter.
• Xeris plans to increase full-year SG&A by approximately $50 million and R&D by $25 million versus 2025, primarily to support RECORLEV expansion and the planned year-end Phase III start for XP-8121; management expects R&D spending to rise further as the trial ramps in 2027.

Xeris Biopharma Trading Down 9.2%

Shares of XERS stock traded down $0.75 on Thursday, reaching $7.36. The company had a trading volume of 3,723,333 shares, compared to its average volume of 1,503,106. The stock has a market cap of $1.27 billion, a PE ratio of 122.67 and a beta of 0.66. The company has a 50-day moving average of $7.64 and a 200-day moving average of $6.79. The company has a current ratio of 2.12, a quick ratio of 1.50 and a debt-to-equity ratio of 17.00. Xeris Biopharma has a 12 month low of $5.25 and a 12 month high of $10.08.

Insider Buying and Selling at Xeris Biopharma

In related news, Director Dawn Halkuff sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $6.09, for a total transaction of $121,800.00. Following the completion of the transaction, the director owned 95,000 shares in the company, valued at approximately $578,550. The trade was a 17.39% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 16,667 shares of the company’s stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $6.06, for a total transaction of $101,002.02. Following the completion of the sale, the insider directly owned 1,176,506 shares of the company’s stock, valued at $7,129,626.36. The trade was a 1.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 266,499 shares of company stock worth $1,996,417 over the last ninety days. 4.35% of the stock is owned by corporate insiders.

Institutional Trading of Xeris Biopharma

Several hedge funds have recently added to or reduced their stakes in the business. Corient Private Wealth LLC bought a new stake in shares of Xeris Biopharma in the fourth quarter worth about $84,000. Jain Global LLC bought a new position in shares of Xeris Biopharma during the 4th quarter valued at about $87,000. Mercer Global Advisors Inc. ADV acquired a new position in shares of Xeris Biopharma in the 3rd quarter valued at approximately $85,000. Tower Research Capital LLC TRC grew its position in shares of Xeris Biopharma by 913.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock valued at $81,000 after purchasing an additional 15,678 shares during the period. Finally, Modern Wealth Management LLC acquired a new position in shares of Xeris Biopharma in the 2nd quarter valued at approximately $83,000. Institutional investors and hedge funds own 42.75% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings raised Xeris Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, July 23rd. Four research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Xeris Biopharma currently has an average rating of “Moderate Buy” and a consensus target price of $10.80.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.